Protagonist Therapeutics Inc
NASDAQ:PTGX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.83
48.43
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PTGX stock under the Base Case scenario is 18.59 USD. Compared to the current market price of 44.94 USD, Protagonist Therapeutics Inc is Overvalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Protagonist Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PTGX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Protagonist Therapeutics Inc
Balance Sheet Decomposition
Protagonist Therapeutics Inc
Current Assets | 476.8m |
Cash & Short-Term Investments | 468.7m |
Receivables | 2.7m |
Other Current Assets | 5.4m |
Non-Current Assets | 127.1m |
Long-Term Investments | 114.6m |
PP&E | 12.3m |
Other Non-Current Assets | 225k |
Current Liabilities | 44.6m |
Accounts Payable | 3m |
Accrued Liabilities | 20.7m |
Other Current Liabilities | 20.9m |
Non-Current Liabilities | 27.4m |
Other Non-Current Liabilities | 27.4m |
Earnings Waterfall
Protagonist Therapeutics Inc
Revenue
|
323.8m
USD
|
Operating Expenses
|
-174.7m
USD
|
Operating Income
|
149.1m
USD
|
Other Expenses
|
21.7m
USD
|
Net Income
|
170.8m
USD
|
Free Cash Flow Analysis
Protagonist Therapeutics Inc
USD | |
Free Cash Flow | USD |
PTGX Profitability Score
Profitability Due Diligence
Protagonist Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Protagonist Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
PTGX Solvency Score
Solvency Due Diligence
Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PTGX Price Targets Summary
Protagonist Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PTGX is 55.46 USD with a low forecast of 43.43 USD and a high forecast of 68.25 USD.
Dividends
Current shareholder yield for PTGX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PTGX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 118 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.
Contact
IPO
Employees
Officers
The intrinsic value of one PTGX stock under the Base Case scenario is 18.59 USD.
Compared to the current market price of 44.94 USD, Protagonist Therapeutics Inc is Overvalued by 59%.